Podcast: Play in new window | Download
Subscribe: Google Podcasts | RSS
Markus Roggen, President and Chief Scientific Officer at DELIC Labs, is back to discuss the challenges that come with testing psilocybin and psychedelic mushrooms.
Markus has been in the cannabis industry since 2014 and has held several executive positions in analytical and production companies. His research into process optimization and analytical methods has been recognized with a number of awards, and he has become a trusted advisor and mentor to multiple startups, startup accelerators and organizations, including CannMed. At DELIC labs, Markus and his team have spent the past two years developing analytical methods for psilocybin and other psychedelics, which is an emerging medicinal industry that is following in the footsteps of the cannabis industry.
Our conversation covers the following topics:
- The regulations in Canada that make it favorable for psychedelic research
- What does psilocybin medicine look like and how is it created
- Whether psilocybin will become a mass-market recreational product
- How psilocybin analytics differs from cannabinoid analytics
- The difference between psilocybin and psilocin
- What types of impurities/contaminants are a concern with psilocybin products
- The process of discovering new tryptamine compounds in psychedelic mushrooms
- Future research projects (psilocybin extraction and optimal storage conditions)
Thanks to This Episode’s Sponsor: Agilent Technologies
Whether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Our team of experts can develop, implement, and optimize methods to get you up and running quickly.
Learn more at www.agilent.com/chem/cannabis
Additional Resources